Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-201 vs Keytruda in Advanced Melanoma
NCT05986331Phase 3Active, not recruiting
- Sponsor
- BIOCAD
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of BCD-201 in melanoma, sponsored by BIOCAD. Started Jul 2022; status: active, not recruiting.
02
Drugs
BCD-201
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05986331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05986331.